Messengers of tolerance

Bontha, Sai Vineela; Fernandez-Piñeros, Angela; Maluf, Daniel G.; Mas, Valeria R.

doi:10.1016/j.humimm.2018.01.008

Cited by 4 publications

(2 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All these approaches need to be validated, but they may pave the way for the identification of tolerance biomarkers, with important implications on management of immunosuppressive therapy [ 193 ]. The state-of-the-art of this family of biomarkers was recently analyzed in several reviews [ 2 , 194 , 195 ] and is beyond the scope of this work.…”

Section: Current Limits and Perspectives Of Biomarkers In Renal Trmentioning

confidence: 99%

Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction

Quaglia

Merlotti

Guglielmetti

et al. 2020

IJMS

View full text Add to dashboard Cite

New biomarkers of early and late graft dysfunction are needed in renal transplant to improve management of complications and prolong graft survival. A wide range of potential diagnostic and prognostic biomarkers, measured in different biological fluids (serum, plasma, urine) and in renal tissues, have been proposed for post-transplant delayed graft function (DGF), acute rejection (AR), and chronic allograft dysfunction (CAD). This review investigates old and new potential biomarkers for each of these clinical domains, seeking to underline their limits and strengths. OMICs technology has allowed identifying many candidate biomarkers, providing diagnostic and prognostic information at very early stages of pathological processes, such as AR. Donor-derived cell-free DNA (ddcfDNA) and extracellular vesicles (EVs) are further promising tools. Although most of these biomarkers still need to be validated in multiple independent cohorts and standardized, they are paving the way for substantial advances, such as the possibility of accurately predicting risk of DGF before graft is implanted, of making a “molecular” diagnosis of subclinical rejection even before histological lesions develop, or of dissecting etiology of CAD. Identification of “immunoquiescent” or even tolerant patients to guide minimization of immunosuppressive therapy is another area of active research. The parallel progress in imaging techniques, bioinformatics, and artificial intelligence (AI) is helping to fully exploit the wealth of information provided by biomarkers, leading to improved disease nosology of old entities such as transplant glomerulopathy. Prospective studies are needed to assess whether introduction of these new sets of biomarkers into clinical practice could actually reduce the need for renal biopsy, integrate traditional tools, and ultimately improve graft survival compared to current management.

show abstract

Section: Current Limits and Perspectives Of Biomarkers In Renal Trmentioning

confidence: 99%

Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction

Quaglia

Merlotti

Guglielmetti

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Outcomes following LT have significantly improved over the past three decades, and the use of modern immunosuppressant agents has been an important factor in this regard [62]. Unfortunately, the need for long-term IS is associated with serious complications and increases the chances of toxicities, rates of opportunistic infection, and malignancy [62][63][64]. For example, the use of CNIs increases the incidence of chronic kidney disease (CKD) in LT recipients [65].…”

Section: Immunosuppression Weaning In Liver Transplantationmentioning

confidence: 99%

European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation

Berenguer,

de Martin,

Hessheimer

et al. 2023

Transpl Int

Self Cite

View full text Add to dashboard Cite

Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article.

show abstract